AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Jul 22, 2022

JAK inhibitors revolutionize dermatology

The journey from cancer therapy to skin disorders.


Brett A. King, MD, PhD, FAAD
Brett A. King, MD, PhD, FAAD

P015 – JAK Inhibitors: A Therapeutic Revolution in Dermatology
Friday, July 22 | 1 – 4 p.m.
Room 110

Tracking the incredible transformation of Janus kinase (JAK) inhibitors for the treatment of hematologic cancer to its current use in treating a host of dermatologic diseases is storytelling at its best. It’s also the focus of today’s session, P015 – JAK Inhibitors: A Therapeutic Revolution in Dermatology.  

Evolution of versatile treatment option

JAK inhibitors first received approval from the Food and Drug Administration in 2010 for myelofibrosis, a hematologic cancer. Today, this class of medicines is showing efficacy in the treatment of alopecia areata, vitiligo, atopic dermatitis, psoriasis, lichen planus, granuloma annulare, and other dermatologic conditions.

“JAK inhibitors make possible the treatment of several diseases that historically have been refractory to treatment,” said Brett A. King, MD, PhD, FAAD, associate professor of dermatology at the Yale School of Medicine. “At last, approvals of JAK inhibitors in dermatology are happening. In September 2021, there was FDA approval of a topical JAK inhibitor for atopic dermatitis, then two oral JAK inhibitors for atopic dermatitis in January. In June, the FDA approved an oral JAK inhibitor for alopecia areata." The FDA also recently approved topical ruxolitinib for the treatment of nonsegmental vitiligo in patients aged 12 or older.

Implications for dermatology

Dr. King was among the first to report patients with dermatologic disease who were treated with JAK inhibitors. The first report in June 2014 was a young man with alopecia universalis and psoriasis who regrew all his hair taking tofacitinib. A year later, Dr. King reported dramatic repigmentation of a patient with vitiligo, also treated with tofacitinib.

“I doubt ‘alopecia areata’ was in the vocabulary of any drug company at the time of that report,” Dr. King said. “Then, in June 2015, at the same time as the vitiligo report and two years before dupilumab was approved, I published a series of six patients with severe atopic dermatitis treated successfully with tofacitinib. Seven to eight years later and several JAK inhibitors are approved in these same diseases — that is light speed in medicine!”

Off-label uses and mechanisms

During the session, Dr. King will also discuss off-label and now on-label use of JAK inhibitors as well as JAK inhibitor mechanism of action and safety.

“It will be a really rich and engaging three hours,” Dr. King said.  

With the recent approvals of different JAK inhibitors in dermatology, including the latest one, baricitinib, for severe alopecia areata — the first FDA-approved treatment for the disease — it’s impossible to ignore this class of medicines.

Managing risks and benefits

There is a potential downside, however. JAK inhibitors carry a boxed warning for malignancy, serious infections, major cardiovascular events, mortality, and thrombosis.

“We know the risks exist and we should not downplay them,” Dr. King said. “It is important, however, to know the data, which show that the risks are very, very low.”

“Much of the boxed warning for JAK inhibitors, as a class, comes from a long-term study of tofacitinib in patients with moderate-to-severe rheumatoid arthritis, 50 years of age and older with at least one cardiovascular risk factor, a mean BMI of 30, all of whom were taking methotrexate and 57% of whom were also taking prednisone,” he continued. “The vast majority of our patients in dermatology are not the same patients as in that trial.”

“I’m not advocating that we dismiss that trial but rather let’s learn from it,” Dr. King added. “We might not want to use a JAK inhibitor in a 60-year-old patient who is morbidly obese or has uncontrolled hypertension. Using a JAK inhibitor, like using any other medication, is about managing risks and benefits to best serve our patients.” 

Visit AAD DermWorld Meeting News Central for more articles.

Interesting Stories
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
More in 2022 AAD Innovation Academy
Keira L. Barr, MD, FAAD
2022 AAD Innovation Academy
Unlocking the secrets of mind-body therapy
Jul 29, 2022
Robert T. Brodell, MD, FAAD
2022 AAD Innovation Academy
Fox Lecture: Access belongs to everyone
Jul 29, 2022
Img 9508
2022 AAD Innovation Academy
AAD debuts Innovation Academy in Vancouver
Jul 29, 2022
Edit Olasz Harken, MD, PhD, FAAD
2022 AAD Innovation Academy
Your name can be your skin care brand
Jul 29, 2022
Pearl E. Grimes, MD, FAAD
2022 AAD Innovation Academy
Kelly Lectureship traces advances in pigmentary diseases
Jul 29, 2022
Pearl Grimes, MD, FAAD, and Robert T. Brodell, MD, FAAD, FRCP
2022 AAD Innovation Academy
Saturday’s named lectureships take the stage
Jul 23, 2022
Jason B. Lee, MD, FAAD
2022 AAD Innovation Academy
How are your diagnostic skills?
Jul 23, 2022
Lindsay Strowd, MD, FAAD
2022 AAD Innovation Academy
Consultive dermatology plugs in post pandemic
Jul 23, 2022
Mehdi Rashighi, MD, FAAD
2022 AAD Innovation Academy
Game-changing new treatments evolve for dermatologic conditions
Jul 23, 2022
Carolyn Goh, MD, FAAD
2022 AAD Innovation Academy
New approaches to managing hair disorders
Jul 23, 2022
So Yeon Paek, MD, FAAD
2022 AAD Innovation Academy
Laser focused
Jul 22, 2022
Ascend Derm Tank Graphic2
2022 AAD Innovation Academy
Dive into the excitement of Derm Tank!
Jul 22, 2022
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.